Literature DB >> 15848731

Ovarian transplant: a new frontier.

P Mhatre1, J Mhatre, R Magotra.   

Abstract

Two cases of orthotopic ovarian transplantations were performed on patients diagnosed to have Turner's syndrome (ovarian dysgenesis) with primary amenorrhea, short stature, and absent secondary sexual characters. Chromosomal analysis showed 45XO pattern. Both transplants were living related from a sister and from a mother. In both the cases the donor and the recipient were immunologically matched by blood group, histocompatibility antigens (HLA), and lymphocyte cross-match done twice. The donor ovaries were dissected extraperitoneally to have long vascular pedicles. In the first case the donor ovarian vein was sutured end-to-side to external iliac vein and the ovarian artery was sutured to the inferior epigastric artery end-to-end using an operative microscope. The ovary was placed in the orthotopic position transperitoneally. Follow-up for 2.5 years has shown regular menstruations, documented ovulations, rise in hormonal levels, and development of secondary sexual characters. In the second case there was no large vein available for anastomosis so that an avascular orthotopic transplantation was performed. The ovarian cortex was dissected in a fan-shaped manner of 0.5-cm strips. Two grafts sutured onto surgicel were placed orthotopically in the ovarian fossa and the remaining ones were placed into the broad ligament. One month follow-up shows good take-up and follicular development on USG, power-angio, and MRI. Hormonal rise has indicated functioning graft. Immunosuppression was achieved in both cases using cyclosporine (4 mg/kg) and prednisolone (2 mg/kg).

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15848731     DOI: 10.1016/j.transproceed.2004.11.083

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  8 in total

1.  Allogeneic ovarian transplantation using immunomodulator preimplantation factor (PIF) as monotherapy restored ovarian function in olive baboon.

Authors:  Michael Feichtinger; Eytan R Barnea; Atunga Nyachieo; Mats Brännström; S Samuel Kim
Journal:  J Assist Reprod Genet       Date:  2017-11-11       Impact factor: 3.412

Review 2.  Applicability of adult techniques for ovarian preservation to childhood cancer patients.

Authors:  Laura Detti; Daniel C Martin; Lucy J Williams
Journal:  J Assist Reprod Genet       Date:  2012-07-21       Impact factor: 3.412

3.  Optimizing cryoprotectant perfusion conditions for intact ovary: a bovine model.

Authors:  Jian-Min Zhang; Ying-Chun Zhang; Li-Hong Ruan; Heng-Cai Wang
Journal:  J Assist Reprod Genet       Date:  2012-08-17       Impact factor: 3.412

4.  Can frozen-thawed human ovary withstand refreezing-rethawing in the form of cortical strips?

Authors:  Camille Hossay; Alessandra Camboni; Luciana Cacciottola; Thu Y T Nguyen; Rossella Masciangelo; Jacques Donnez; Marie-Madeleine Dolmans
Journal:  J Assist Reprod Genet       Date:  2020-10-06       Impact factor: 3.412

Review 5.  Strategies for fertility preservation in young patients with cancer: a comprehensive approach.

Authors:  Devika Gunasheela; Sulochana Gunasheela
Journal:  Indian J Surg Oncol       Date:  2014-02-26

Review 6.  Female fertility: is it safe to "freeze?".

Authors:  Lu Zhang; Li-Ying Yan; Xu Zhi; Jie Yan; Jie Qiao
Journal:  Chin Med J (Engl)       Date:  2015-02-05       Impact factor: 2.628

7.  Comparison of vitrification and conventional slow freezing for cryopreservation of ovarian tissue with respect to the number of intact primordial follicles: A meta-analysis.

Authors:  Xin-Hui Zhou; Dan Zhang; Jin Shi; Yi-Jun Wu
Journal:  Medicine (Baltimore)       Date:  2016-09       Impact factor: 1.889

8.  Successful fertility following optimized perfusion and cryopreservation of whole ovary and allotransplantation in a premature ovarian insufficiency rat model.

Authors:  Yan Ding; Jia-Liang Shao; Jun-Wei Li; Ying Zhang; Kai-Hua Hong; Ke-Qin Hua; Xiang Wang
Journal:  J Ovarian Res       Date:  2018-05-02       Impact factor: 4.234

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.